Inozyme Pharma Raises $67 Million in Series A2 Financing to Develop Therapies for Rare Mineralization Disorders
A biotechnology company developing novel medicines to treat rare, debilitating, and life-threatening mineralization disorders, today announced that the Company raised $67 million in a Series A2 financing led by Pivotal bioVenture Partners and Sofinnova Investments. Cross-over investors, including RA Capital Management, Cowen Healthcare Investments, and Rock Springs Capital, as well as the Company’s previous investors, Longitude Capital, NEA, Novo Holdings, and Sanofi Ventures, also joined this round.
Inozyme Pharma is a biotechnology company committed to developing novel medicines for the treatment of rare mineralization disorders. Inozyme Pharma was founded in 2017 by Joseph Schlessinger Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc., MBA. The Company licensed technology from Yale University, developed in the laboratory of Dr. Braddock.